Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial

Nita Bhandari PhD a, Temsunaro Rongsen-Chandola MSc a, Ashish Bavdekar DNB b, Jacob John MD c, Kalpana Antony MBA d, Sunita Taneja PhD a, Nidhi Goyal DPH a, Anand Kawade MD b, Prof Gagandeep Kang PhD c, Sudeep Singh Rathore MBBS a, Sanjay JuvekarPhD b, Prof Jayaprakash Muliyil DrPH c, Alok Arya MPharm a, Hanif Shaikh MPharm b, Vinod Abraham MPH c, Prof Sudhanshu VratiPhD e, Michael Proschan PhD f, Robert Kohberger PhD g *, Georges Thiry PhD h, Roger Glass PhD f, Prof Harry B Greenberg MD i,George Curlin MD f, Krishna Mohan PhD j, G V J A Harshavardhan BVSc j, Sai Prasad MBA j, T S Rao PhD k, John Boslego MD m, Dr Prof Maharaj Kishan Bhan MD l , for the India Rotavirus Vaccine Group†
Summary

Background

Rotavirus is the most common cause of severe dehydrating gastroenteritis in developing countries.
Safe, effective, and affordable rotavirus vaccines are needed in these countries. We aimed to assess the efficacy and tolerability of a monovalent human-bovine rotavirus vaccine for severe rotavirus gastroenteritis in low-resource urban and rural settings in India.

Methods

We did a randomised double-blind, placebo-controlled, multicentre trial at three sites in Delhi (urban), Pune (rural), and Vellore (urban and rural) between March 11, 2011, and Nov 5, 2012.
Infants aged 6—7 weeks were randomly assigned (2:1), via a central interactive voice or web response system with a block size of 12, to receive either three doses of oral human-bovine natural reassortant vaccine (116E) or placebo at ages 6—7 weeks, 10 weeks, and 14 weeks. Infants’ families, study investigators, paediatricians in referral hospitals, laboratory staff, and committee members were all masked to treatment allocation.

The primary outcome was incidence of severe rotavirus gastroenteritis (?11 on the Vesikari scale). Efficacy outcomes and adverse events were ascertained through active surveillance. Analysis was by intention to treat and per protocol. The trial is registered with Clinical Trial Registry—India (CTRI/2010/091/000102) and ClinicalTrials.gov (NCT01305109).

Findings
4532 infants were assigned to receive the 116E vaccine and 2267 to receive placebo, of whom 4354 (96%) and 2187 (96%) infants, respectively, were included in the primary per-protocol efficacy analysis.
71 events of severe rotavirus gastroenteritis were reported in 4752 person-years in infants in the vaccine group compared with 76 events in 2360 person-years in those in the placebo group; vaccine efficacy against severe rotavirus gastroenteritis was 53•6% (95% CI 35•0—66•9; p=0•0013) and 56•4% (36•6—70•1; p<0•0001) in the first year of life.
The number of infants needed to be immunised to prevent one severe rotavirus gastroenteritis episode was 55 (95% CI 37—97).
The incidence of severe rotavirus gastroenteritis per 100 person-years was 1•5 in the vaccine group and 3•2 in the placebo group, with an incidence rate ratio of 0•46 (95% CI 0•33—0•65). Prevalence of immediate, solicited, and serious adverse events was similar in both groups. One case of urticaria in the vaccine group and one each of acute gastroenteritis and suspected sepsis in the placebo group were regarded as related to the study product. We recorded six cases of intussusception in the vaccine group and two in the placebo group, all of which happened after the third dose. 25 (<1%) infants in the vaccine group and 17 (<1%) in the placebo group died; no death was regarded as related to the study product.

Interpretation
Monovalent human-bovine (116E) rotavirus vaccine is effective and well tolerated in Indian infants.

G Mohan.